GlassScriptPhysician profile
Jahangir Adil
NPI 1477587517
$3,412.15
in general payments reported to CMS, 2019-2025
28 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $141 · 2021: $72.29 · 2022: $478 · 2023: $375 · 2024: $745 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.87 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $598.37 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $341.58 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $324.00 | 2019-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $238.42 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $237.23 | 2022-2025 | Aristada, Vivitrol, Vivitrol |
| Indivior INC. | $186.93 | 2024-2025 | Sublocade |
| Pfizer INC. | $182.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.11 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $130.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $123.37 | 2024-2025 | Fanapt, Hetlioz |
| Braeburn INC. | $99.55 | 2023-2025 | Brixadi |
| Axsome Therapeutics, INC. | $97.84 | 2024-2025 | Auvelity |
| Biocompatibles, INC. | $91.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.73 | 2024-2025 | Cobenfy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $62.43 | 2019-2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $53.54 | 2024 | Uzedy |
| Neurocrine Biosciences, INC. | $47.47 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.12 | 2025 | Caplyta |
| Amgen INC. | $41.73 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $40.12 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $39.84 | 2019 | |
| Astellas Pharma US INC | $32.19 | 2020-2025 | Veozah |
| Glaxosmithkline, LLC. | $26.36 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $21.21 | 2022 | |
| Allergan, INC. | $18.04 | 2020 | |
| Orexo US, INC. | $14.65 | 2019 | |
| Merck Sharp & Dohme LLC | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jahangir Adil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.